Supplementary Figure 6 from Activated ERBB2/HER2 Licenses Sensitivity to Apoptosis upon Endoplasmic Reticulum Stress through a PERK-Dependent Pathway

Martín-Pérez, Rosa; Palacios, Carmen; Yerbes, Rosario; Cano-González, Ana; Iglesias-Serret, Daniel; Gil, Joan; Reginato, Mauricio J.; López-Rivas, Abelardo

doi:10.1158/0008-5472.22400759.v1

Supplementary Figure 6 from Activated ERBB2/HER2 Licenses Sensitivity to Apoptosis upon Endoplasmic Reticulum Stress through a PERK-Dependent Pathway

journal contribution

posted on 2023-03-30, 22:21 authored by Rosa Martín-Pérez, Carmen Palacios, Rosario Yerbes, Ana Cano-González, Daniel Iglesias-Serret, Joan Gil, Mauricio J. Reginato, Abelardo López-Rivas

PDF file - 23KB, TRAIL-independent induction of apoptosis upon ER stress.

History

ARTICLE ABSTRACT

HER2/Neu/ERBB2 is a receptor tyrosine kinase overexpressed in approximately 20% of human breast tumors. Truncated or mutant isoforms that show increased oncogenicity compared with the wild-type receptor are found in many breast tumors. Here, we report that constitutively active ERBB2 sensitizes human breast epithelial cells to agents that induce endoplasmic reticulum stress, altering the unfolded protein response (UPR) of these cells. Deregulation of the ERK, AKT, and mTOR activities elicited by mutant ERBB2 was involved in mediating this differential UPR response, elevating the response to endoplasmic reticulum stress, and apoptotic cell death. Mechanistic investigations revealed that the increased sensitivity of mutant ERBB2-expressing cells to endoplasmic reticulum stress relied upon a UPR effector signaling involving the PERK–ATF4–CHOP pathway, upregulation of the proapoptotic cell surface receptor TRAIL-R2, and activation of proapoptotic caspase-8. Collectively, our results offer a rationale for the therapeutic exploration of treatments inducing endoplasmic reticulum stress against mutant ERBB2-expressing breast tumor cells. Cancer Res; 74(6); 1766–77. ©2014 AACR.